

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Neurology				
Depression	Serotonin (5-HT) transporter (SLC6A4; SERT); solute carrier family 6 neurotransmitter transporter noradrenalin member 2 (SLC6A2; NET); solute carrier family 6 neurotransmitter transporter dopamine member 3 (SLC6A3; DAT1)	<p><i>In vitro</i> and murine studies suggest that a class of serotonin, noradrenalin and dopamine reuptake inhibitors (SNDRI) could help treat depression.</p> <p><i>In vitro</i> testing of synthetic azabicyclohexane analogs identified multiple compounds that inhibited SERT, NET and DAT at low nanomolar concentrations. A lead compound showed SNDRI activity in the prefrontal cortices of normal rats. In three mouse models of depression, the lead also reduced depression-like behaviors compared with no treatment. Future studies could include efficacy and safety testing of other compounds in the series.</p> <p>SciBX 3(9); doi:10.1038/scibx.2010.283 Published online March 4, 2010</p>	Patented by Glaxo Group Ltd.; licensing status unavailable	<p>Micheli, F. <i>et al. J. Med. Chem.</i>; published online Feb. 19, 2010; doi:10.1021/jm901818u</p> <p>Contact: Fabrizio Micheli, GlaxoSmithKline Medicine Research Centre, Verona, Italy e-mail: Fabrizio.E.Micheli@gsk.com</p>